Results 181 to 190 of about 22,180 (202)

Aripiprazole

Reactions Weekly, 2018
  +4 more sources

Aripiprazole (ABILIFY MAINTENA®): A Review of Its Use as Maintenance Treatment for Adult Patients with Schizophrenia

Drugs, 2014
Matt Shirley, Shirley Matt, Perry Caroline M   +2 more
exaly  

Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil

Expert Review of Clinical Pharmacology, 2016
Leslie Citrome
exaly  

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

Schizophrenia Research, 2003
Stephen R Marder, Robert D Mcquade, Ronald Marcus   +2 more
exaly  

A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents With Irritability Associated With Autistic Disorder

Journal of the American Academy of Child and Adolescent Psychiatry, 2009
Randall Owen, George Manos, Robert D Mcquade   +2 more
exaly  

Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability

Clinical Therapeutics, 2004
Nick C Patel
exaly  

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

European Journal of Pharmacology, 2002
Katsura Tottori, Tetsuro Kikuchi, C Anthony Altar   +2 more
exaly  

Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology

CNS Neuroscience & Therapeutics, 2004
Douglas J Sheffler, Bryan L Roth
exaly  

Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties

European Journal of Pharmacology, 2006
Charlie Reavill, Declan N C Jones, Ian T Forbes   +2 more
exaly  

Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology

Neuropsychopharmacology, 2003
L A Chiodo, David R Sibley, Bryan L Roth
exaly